Acknowledgements

 The content of this section has been developed in collaboration between COR2ED GmbH (an Independent Medical Education Company) and the experts serving as Scientific Directors on this programme:

  • Prof. Hans Gelderblom, Leiden University Medical Center, The Netherlands - Clinical Oncologist
  • Prof. Claus-Henning Koehne, Klinikum Oldenburg, Germany - Clinical Oncologist
  • Dr. Roelof W F van Leeuwen, Erasmus MC Cancer Institute, The Netherlands - Clinical Pharmacist
  • Dr. Vincent Launay-Vacher, Service ICAR, Pitié-Salpêtrière University Hospital, France - Clinical Pharmacologist

Medical writing support was provided by Mark English, PhD, of COR2Ed GmbH. Subsequently the content was donated to the European Society for Medical Oncology (ESMO).

Bayer Healthcare

ESMO, COR2ED GmbH and the Scientific Directors wish to thank Bayer HealthCare for their support with an Independent Medical Grant. Within the context of this Independent Medical Grant Bayer HealthCare had no influence over the content.

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.

Last update: 22 July 2015